Cargando…

Real-world data from expanded access programmes in health technology assessments: a review of NICE technology appraisals

OBJECTIVES: To quantify and characterise the usage of expanded access (EA) data in National Institute for Health and Care Excellence (NICE) technology appraisals (TAs). EA offers patients who are ineligible for clinical trials or registered treatment options, access to investigational therapies. Alt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Polak, Tobias B, Cucchi, David GJ, van Rosmalen, Joost, Uyl-de Groot, Carin A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Health Policy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739059/ https://www.ncbi.nlm.nih.gov/pubmed/34992108 http://dx.doi.org/10.1136/bmjopen-2021-052186

Ejemplares similares

Incremental benefits of novel pharmaceuticals in the UK: a cross-sectional analysis of NICE technology appraisals from 2010 to 2020
por: Polak, Tobias B, et al.
Publicado: (2022)

Expanded Access as a source of real‐world data: An overview of FDA and EMA approvals
por: Polak, Tobias B., et al.
Publicado: (2020)

Generating Evidence from Expanded Access Use of Rare Disease Medicines: Challenges and Recommendations
por: Polak, Tobias B., et al.
Publicado: (2022)

Results from Expanded Access Programs: A Review of Academic Literature
por: Polak, Tobias B., et al.
Publicado: (2023)

Audit of data redaction practices in NICE technology appraisals from 1999 to 2019
por: Osipenko, Leeza
Publicado: (2021)

A qualitative study of manufacturers' submissions to the UK NICE single technology appraisal process
por: Kaltenthaler, Eva C, et al.
Publicado: (2012)

NICE guidance: a comparative study of the introduction of the single technology appraisal process and comparison with guidance from Scottish Medicines Consortium
por: Ford, John A, et al.
Publicado: (2012)

The impact of rarity in NICE’s health technology appraisals
por: Clarke, Sophie, et al.
Publicado: (2021)

Biologic agents for rheumatoid arthritis—negotiating the NICE technology appraisals
por: Kiely, Patrick D. W., et al.
Publicado: (2012)

Decision making in NICE single technological appraisals: How does NICE incorporate patient perspectives?
por: Hashem, Ferhana, et al.
Publicado: (2017)

Evaluation of US oncology electronic health record real-world data to reduce uncertainty in health technology appraisals: a retrospective cohort study
por: Mpofu, Philani, et al.
Publicado: (2023)

NICE technology appraisals: working with multiple levels of uncertainty and the potential for bias
por: Brown, Patrick, et al.
Publicado: (2011)

A Review of Economic Models Submitted to NICE’s Technology Appraisal Programme, for Treatments of T1DM & T2DM
por: Daly, Marie-Josée, et al.
Publicado: (2022)

The NICE Evidence Standards Framework for digital health and care technologies – Developing and maintaining an innovative evidence framework with global impact
por: Unsworth, Harriet, et al.
Publicado: (2021)

Flexibility in assessment of rare disease technologies via NICE's single technology appraisal route: a thematic analysis
por: Hale, George, et al.
Publicado: (2023)

It’s not evidence, it’s insight: bringing patients’ perspectives into health technology appraisal at NICE
por: Staley, Kristina, et al.
Publicado: (2016)

Impact of the National Institute for Health and Care Excellence (NICE) guidance on medical technology uptake: analysis of the uptake of spinal cord stimulation in England 2008–2012
por: Vyawahare, Bharati, et al.
Publicado: (2014)

The NICE Medical Technologies Evaluation Programme (MTEP): manufacturer submission challenges
por: Sprange, Kirsty, et al.
Publicado: (2012)

A Review of Issues Affecting the Efficiency of Decision Making in the NICE Single Technology Appraisal Process
por: Walton, M. J., et al.
Publicado: (2019)

CERN Technology on display in Nice
Publicado: (2000)

CERN Technology on Display in Nice
Publicado: (2000)

Access to adults’ hearing aids: policies and technologies used in eight countries
por: Yong, Michael, et al.
Publicado: (2019)

Pandemic Telemedicine Technology Response Plan and Technology Assessment Phase 2: Pandemic Action Plan Key Issues and Technology Solutions for Health Care Delivery Organizations in a Pandemic
por: VanderWerf, Mark, et al.
Publicado: (2022)

Issues Related to the Frequency of Exploratory Analyses by Evidence Review Groups in the NICE Single Technology Appraisal Process
por: Kaltenthaler, Eva, et al.
Publicado: (2016)

Cenegermin for Treating Neurotrophic Keratitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Fleeman, Nigel, et al.
Publicado: (2019)

Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Wijnen, Ben, et al.
Publicado: (2022)

Strengthening the Expanded Programme on Immunization in Africa: Looking beyond 2015
por: Machingaidze, Shingai, et al.
Publicado: (2013)

Expanding hermeneutics to the world of technology
por: Zovko, Jure
Publicado: (2020)

Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin’s Lymphoma: A NICE Single Technology Appraisal
por: Greenhalgh, Janette, et al.
Publicado: (2013)

Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Mistry, Hema, et al.
Publicado: (2017)

Filgotinib for Moderate to Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Grimm, Sabine E., et al.
Publicado: (2021)

Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Bresnahan, Rebecca, et al.
Publicado: (2023)

When Does NICE Recommend the Use of Health Technologies Within a Programme of Evidence Development?: A Systematic Review of NICE Guidance
por: Longworth, Louise, et al.
Publicado: (2013)

Rituximab in Combination with Corticosteroids for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A NICE Single Technology Appraisal
por: Latimer, Nicholas R., et al.
Publicado: (2014)

Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Ramaekers, Bram L. T., et al.
Publicado: (2018)

Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Ramaekers, Bram L. T., et al.
Publicado: (2018)

Methods for selecting the best evidence to inform a NICE technology appraisal on selective internal radiation therapies for hepatocellular carcinoma
por: Wade, Ros, et al.
Publicado: (2020)

Correction to: Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Mistry, Hema, et al.
Publicado: (2019)

A change in the NICE guidelines on antibiotic prophylaxis: British Heart Valve Society update
por: Chambers, John B, et al.
Publicado: (2017)

Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal
por: Büyükkaramikli, Nasuh C., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_97749o1e8jogv85f2q5mak1dm1